<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04245397</url>
  </required_header>
  <id_info>
    <org_study_id>SX682-MDS-102</org_study_id>
    <secondary_id>R44HL142389-01</secondary_id>
    <nct_id>NCT04245397</nct_id>
  </id_info>
  <brief_title>SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy</brief_title>
  <official_title>A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syntrix Biosystems, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Syntrix Biosystems, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting&#xD;
      toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients&#xD;
      with Myelodysplastic Syndromes (MDS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive twice daily oral SX-682 for six 28 day cycles. If patients are&#xD;
      responding well to the treatment they can continue SX-682 treatment. The first participants&#xD;
      will be administered 25 mg orally twice daily. Unless dose limiting toxicities occur,&#xD;
      participants will enroll and receive the following increasing twice daily doses of SX-682: 50&#xD;
      mg, 100 mg, 200 mg, and 400 mg.&#xD;
&#xD;
      After establishing the maximum tolerated dose 40 additional participants will be enrolled at&#xD;
      the maximum tolerated dose (or at the highest dose studied if a maximum tolerated dose is not&#xD;
      identified). Participants will receive continuous SX-682 twice daily oral therapy in 28-day&#xD;
      cycles for a total of 6 cycles. For patients responding well at the end of 6 cycles treatment&#xD;
      may continue until disease progression or an adverse event leads to SX-682 discontinuation.&#xD;
      Except for blood product transfusions, concurrent therapy for Myelodysplastic Syndromes is&#xD;
      not permitted.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>In this sequential model initially participant groups will enroll to receive SX-682 for six 28 day cycles in a dose escalation phase. A 3 + 3 participant design will be used to determine the safe dose. After 6 cycles at the specified dose of SX-682, SX-682 treatment can be continued. Once the safe dose level of SX-682 is determined, then participants will be enrolled at the this safe dose level of SX-682 in an expansion phase.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SX-682 Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 28 days in the 28 day Cycle 1.</time_frame>
    <description>Participants cohorts will be enrolled at increasing doses of SX-682. The highest SX-682 dose tested at which no more than 1 of 6 participants experiences a dose limiting toxicity will define the SX-682 MTD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SX-682 Dose Limiting Toxicities (DLT)</measure>
    <time_frame>Up to 28 days in the 28 day Cycle 1.</time_frame>
    <description>Number of participants experiencing DLTs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants Experiencing a Treatment Response</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 28 days).</time_frame>
    <description>The percentage of participants experiencing a complete remission, partial remission, or stable disease according to the International Working Group Response Criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SX-682 Delayed Dose Limiting Toxicities</measure>
    <time_frame>From the beginning of Cycle 2 to the end of Cycle 6 (each cycle is 28 days).</time_frame>
    <description>Number of delayed DLTs experienced by participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>At the end of Cycle 6 (each cycle is 28 days).</time_frame>
    <description>Number of participants experiencing adverse events (AEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SX-682 Single Dose Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Day 1 of Cycle 1 (each cycle is 28 days).</time_frame>
    <description>Blood samples will be collected before and after the first dose of SX-682 on Day 1 of Cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SX-682 Steady-State Maximum Plasma Concentration (Css max)</measure>
    <time_frame>Day 15 of Cycle 1 (each cycle is 28 days).</time_frame>
    <description>Blood samples will be collected before and after the first dose of SX-682 on Day 15 of Cycle 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SX-682 Steady-State Minimum Plasma Concentration (Css min)</measure>
    <time_frame>Day 15 of Cycle 1 (each cycle is 28 days).</time_frame>
    <description>Blood samples will be collected before and after the first dose of SX-682 on Day 15 of Cycle 1.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Oral Dose of S-682</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SX-682</intervention_name>
    <description>Drug: SX-682 SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)</description>
    <arm_group_label>Oral Dose of S-682</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of MDS by World Health Organization criteria, and either&#xD;
&#xD;
               1. International Prognostic Scoring System (IPSS) low risk or intermediate-1 risk&#xD;
                  without 5q deletion and failed treatment (no response, loss of response,&#xD;
                  progressive disease/treatment intolerance) following:&#xD;
&#xD;
                  i. 4 cycles hypomethylating agent; or ii. 4 cycles hypomethylating agent, or&#xD;
                  lenalidomide or erythropoietin stimulating agent (ESA).&#xD;
&#xD;
               2. IPSS low risk or intermediate-1 risk with 5q deletion and failed treatment&#xD;
                  following:&#xD;
&#xD;
                  i. 4 cycles of lenalidomide and hypomethylating agent; or ii. 4 cycles of&#xD;
                  lenalidomide.&#xD;
&#xD;
               3. IPSS intermediate-2 risk or high risk and failed treatment following 4 cycles&#xD;
                  hypomethylating agent.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2&#xD;
&#xD;
          -  Screening laboratory values:&#xD;
&#xD;
               1. Renal glomerular filtration rate (GFR) ≥ 60 ml/min;&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) ≤ 3.0 times&#xD;
                  upper limit of normal;&#xD;
&#xD;
               3. Bilirubin &lt; 1.5 times upper limit of normal;&#xD;
&#xD;
               4. No history of HIV being HIV positive;&#xD;
&#xD;
               5. No active Hepatitis B or Hepatitis C infection.&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must use study specified contraception.&#xD;
&#xD;
          -  WOCBP demonstrate negative pregnancy test.&#xD;
&#xD;
          -  Not breastfeeding.&#xD;
&#xD;
          -  Men sexually active must use study specified contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of chemotherapeutic agents or experimental agents for MDS within 14 days of the&#xD;
             first day of study drug treatment.&#xD;
&#xD;
          -  Use of erythroid stimulating agents, Granulocyte-colony stimulating factor (G-CSF), or&#xD;
             Granulocyte-macrophage colony-stimulating factor (GM-CSF) within 14 days of the first&#xD;
             day of study drug treatment, or during the study.&#xD;
&#xD;
          -  Mean triplicate heart rate-corrected QT interval (QTc) &gt; 500 msec.&#xD;
&#xD;
          -  Any of the following cardiac abnormalities:&#xD;
&#xD;
               1. QT interval &gt; 480 msec corrected using Fridericia's formula;&#xD;
&#xD;
               2. Risk factors for Torsade de Pointes;&#xD;
&#xD;
               3. Use of medication that prolongs the QT interval;&#xD;
&#xD;
               4. Myocardial infarction ≤ 6 months prior to first day of study drug treatment;&#xD;
&#xD;
               5. Unstable angina pectoris or serious uncontrolled cardiac arrhythmia.&#xD;
&#xD;
          -  Any serious or uncontrolled medical disorder.&#xD;
&#xD;
          -  Prior malignancy within the previous 3 years except for local cancers that have been&#xD;
             cured.&#xD;
&#xD;
          -  Within 14 days of the first study drug treatment requiring systemic treatment with&#xD;
             either corticosteroids or immunosuppressive medications. Corticosteroid adrenal&#xD;
             replacement doses are permitted.&#xD;
&#xD;
          -  Use of other investigational drugs within 30 days of study drug administration.&#xD;
&#xD;
          -  Major surgery within 4 weeks of study drug administration.&#xD;
&#xD;
          -  Live-virus vaccination within 30 days of study drug administration.&#xD;
&#xD;
          -  Allergy to study drug component.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David A Sallman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stuart J Kahn, MD</last_name>
    <phone>2065240214</phone>
    <email>skahn@syntrixbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Clark</last_name>
      <phone>813-745-7362</phone>
      <email>Kimberly.Clark@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>David A Sallman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Chemokine receptor blockade</keyword>
  <keyword>Myeloid-derived supressor cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

